Please assess the completion status of the following clinical trial:

Trial Title: Alisertib for Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed, newly diagnosed acute myelogenous leukemia~* Agree to use an acceptable method for contraception during the entire study treatment period through 4 months after the last dose of MLN8237~* Able to take oral medication and to maintain a fast as required for 2 hours before and 1 hour after MLN8237 administration~Exclusion Criteria:~* Have received systemic antineoplastic therapy, including radiotherapy within 14 days of study treatment, with the exception of hydroxyurea or 6-mercaptopurine for the purposes of cytoreduction~* Pregnant or breastfeeding~* Presence of favorable or better risk cytogenic prognosis~* Prior allogeneic bone marrow or organ transplantation~* Diagnosis of acute bilineal/biphenotypic leukemia~* History of a different malignancy except if disease-free for at least 5 years and at low risk or recurrence; or cervical cancer in situ, basal cell or squamous cell carcinoma of the skin within the past 5 years~* Uncontrolled intercurrent illness~* HIV positive on combination antiretroviral therapy~* Diagnosis of active hepatitis B or C~* Current or history of congestive heart failure NYHA class 3 or 4, or documented diastolic or systolic dysfunction~* Current or history of ventricular or life threatening arrhythmias or diagnosis of long QT syndrome~* Known history of uncontrolled sleep apnea syndrome or other condition that could result in excessive daytime sleepiness~* Requirement for constant administration of proton pump inhibitor, H2 antagonist or pancreatic enzymes~* Systemic infection requiring IV antibiotic therapy within 14 days of first dose of study drug~* Treatment with clinically significant enzyme inducers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Induction: 100 mg/m2/day Cytarabine intravenous, days 1-7 of induction cycle. 12 mg/m2/day Idarubicin intravenous, days 1-3. Alisertib orally, twice a day for one week starting on day 8, dose escalation-starting dose 10 mg PO BID.~Consolidation: Cytarabine 3 g/m2 by IV infusion over 3 hours given every 12 hours on Days 1, 3 and 5 (subjects younger than age 60) or Cytarabine 2 g/m2 per day by IV infusion over 3 hours on days 1-5 (subjects at or older than age 60)

Based on this trial design, predict the completion outcome and termination type (if applicable).